Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics has demonstrated significant clinical progress with relacorilant, particularly in combination with nab-paclitaxel, showing compelling progression-free survival benefits in patients with prior PARPi treatment and those whose disease progressed on PARPi, which enhances its therapeutic portfolio. The company has reported increased demand for its flagship product, Korlym, indicating that sales would likely increase if production capacity were expanded to accommodate this demand, suggesting a strong revenue growth potential moving forward. Furthermore, promising developments from the BELLA Phase 2 trial and additional positive subgroup data bolster the outlook for relacorilant's regulatory success and its expanded application in oncology, underscoring the overall positive trajectory of Corcept Therapeutics's financial prospects.

Corcept Therapeutics is facing potential near-term earnings challenges, primarily due to the recent departure of an executive, which could lead to a downward revision of 2025 revenue guidance in the upcoming financial report. Consequently, the sales forecast for the company's product Korlym has been reduced by approximately 10% for the latter half of 2025, resulting in a revised 2025 revenue estimate of $824 million, which falls below the current guidance range of $850 million to $900 million. Additionally, management turnover may disrupt clinical development efforts and negatively impact the company’s share performance, further contributing to a negative outlook for the stock.